Equillium Net Income Over Time
| EQ Stock | USD 1.57 0.03 1.88% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Equillium Performance and Equillium Correlation. Equillium | Build AI portfolio with Equillium Stock |
Can Biotechnology industry sustain growth momentum? Does Equillium have expansion opportunities? Factors like these will boost the valuation of Equillium. Projected growth potential of Equillium fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Equillium demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.58) | Revenue Per Share | Quarterly Revenue Growth (0.52) | Return On Assets | Return On Equity |
Equillium's market price often diverges from its book value, the accounting figure shown on Equillium's balance sheet. Smart investors calculate Equillium's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Equillium's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Equillium's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Equillium should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Equillium's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Equillium and related stocks such as Cue Biopharma, Coeptis Therapeutics, and NRX Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CUE | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (7.7 M) | (23.2 M) | (39 M) | (36.7 M) | (44.8 M) | (44.2 M) | (53 M) | (50.7 M) | (40.7 M) | (36.6 M) | (38.4 M) |
| COEP | 2.6 M | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (7.1 K) | (2.2 K) | (9.2 M) | (13.4 M) | (37.6 M) | (21.3 M) | (10.9 M) | (9.8 M) | (10.3 M) |
| NRXP | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | 66.1 K | 408.4 K | (51.8 M) | (93.1 M) | (39.8 M) | (30.1 M) | (25.1 M) | (22.6 M) | (23.7 M) |
| OSTX | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (7.4 M) | (6.3 M) | (7.8 M) | (8.9 M) | (8 M) | (8.4 M) |
| IPSC | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (244.8 M) | (53.6 M) | (95.8 M) | (130.9 M) | (136.7 M) | (126.6 M) | (145.6 M) | (152.8 M) |
| TELO | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (854.1 K) | (13.1 M) | (16.5 M) | (16.5 M) | (14.9 M) | (14.1 M) |
| OTLK | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (47.4 M) | (53.3 M) | (38.8 M) | (30.1 M) | (34.5 M) | (35.2 M) | (53.2 M) | (66.1 M) | (59 M) | (75.4 M) | (62.4 M) | (56.2 M) | (59 M) |
| FBIO | (3.8 M) | (36.4 M) | (27.6 M) | (37.2 M) | (20.4 M) | (48.4 M) | (55.1 M) | (66.9 M) | (84.1 M) | (40 M) | (46.5 M) | (64.7 M) | (86.6 M) | (60.6 M) | (46 M) | (41.4 M) | (43.5 M) |
| SPRB | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (13.2 M) | (29.5 M) | (42.3 M) | (46.2 M) | (47.9 M) | (53 M) | (47.7 M) | (50.1 M) |
Equillium and related stocks such as Cue Biopharma, Coeptis Therapeutics, and NRX Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Equillium financial statement analysis. It represents the amount of money remaining after all of Equillium operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Equillium | EQ |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2223 Avenida De |
| Exchange | NASDAQ Exchange |
USD 1.57
Additional Tools for Equillium Stock Analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.